Item 9A. Controls and Procedures
Item 9A. Controls and Procedures
Evaluation of disclosure controls and procedures: We have performed an evaluation under the supervision and with the participation of our management, including our CEO and CFO, of the effectiveness of our disclosure controls and procedures, as defined in Exchange Act Rules 13a-15(e) and 15d-15(e), as of the end of the fiscal year. Based on that evaluation, our CEO and CFO concluded that our disclosure controls and procedures were effective as of December 28, 2025 at a reasonable assurance level to ensure that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures.
Changes in internal control over financial reporting: There were no changes in our internal control over financial reporting during the fiscal quarter ended December 28, 2025 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Management’s report on internal control over financial reporting: Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such terms are defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external purposes in accordance with GAAP. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Under the supervision and with the participation of our management, including our CEO and CFO, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our evaluation under the framework in Internal Control—Integrated Framework, our management concluded that our internal control over financial reporting was effective as of December 28, 2025.
The effectiveness of our internal control over financial reporting as of December 28, 2025 has been audited by KPMG LLP, our independent registered public accounting firm, as stated in their report, which is included in this Item 9A.
Remediation of previously reported material weaknesses: Throughout fiscal year 2025, management completed the implementation and testing of various remediation measures to address the material weaknesses identified in Management’s Report on Internal Control over Financial Reporting as of December 29, 2024. These remediation actions included, but were not limited to, the following:
• Enhanced review and monitoring controls so that information generated from certain software solutions affecting net revenue and used by management in accounting for gross revenue, accounts receivable and in the estimation of accrued rebates is complete and accurate. These controls included:
◦ Upgraded retention requirements for supporting documentation used to evidence management’s review at an appropriate precision level over the completeness and accuracy of the information used in the performance of the controls related to the aforementioned accounts.
◦ Expanded review and monitoring controls related to third-party software solutions SOC 1 reports, including enhancement of the controls identified and tested to support the complementary user entity controls listed in the SOC 1 reports.
• Enhanced tax controls related to our deferred tax assets, including engagement of third-party tax provision advisors with the requisite skills and technical expertise to assist in the assessment and retention of documented evidence showing the evaluation of all available evidence, both positive and negative, to assess the realizability of deferred tax assets.
Based on the remediation efforts and results of management testing, we have concluded the material weaknesses identified as of December 29, 2024 were fully remediated as of December 28, 2025.
116
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Stockholders and the Board of Directors
QuidelOrtho Corporation:
Opinion on Internal Control Over Financial Reporting
We have audited QuidelOrtho Corporation and subsidiaries’ (the Company) internal control over financial reporting as of December 28, 2025, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 28, 2025, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheet of the Company as of December 28, 2025, the related consolidated statements of loss, comprehensive (loss) income, stockholders’ equity, and cash flows for the year ended December 28, 2025, and the related notes (collectively, the consolidated financial statements), and our report dated February 18, 2026 expressed an unqualified opinion on those consolidated financial statements.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s report on internal control over financial reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control Over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
/s/ KPMG LLP
Short Hills, New Jersey
February 18, 2026
117
Item 9B. Other Information
(a) None.
(b) During the last fiscal quarter, no director or officer (as defined in Exchange Act Rule 16a-1(f)) adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement.
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
Not applicable.
118
Part III
Item 10. Directors, Executive Officers and Corporate Governance
The information required by this item is incorporated herein by reference to our 2026 definitive proxy statement to be filed with the SEC within 120 days of the fiscal year ended December 28, 2025 (the “2026 Proxy Statement”), including under the headings “Proposal One - Election of Directors Proposal,” “Corporate Governance,” “ Insider Trading Policy ,” “Executive Officers” and, if applicable, “Delinquent Section 16(a) Reports.”
Item 11. Executive Compensation
The information required by this item is incorporated herein by reference to our 2026 Proxy Statement, including under the headings “Director Compensation,” “Executive Compensation,” “Compensation Committee Interlocks and Insider Participation” and “Compensation Committee Report.”
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
The information required by this item is incorporated herein by reference to our 2026 Proxy Statement, including under the headings “Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters” and “Securities Authorized for Issuance under Equity Compensation Plans.”
Item 13. Certain Relationships and Related Transactions, and Director Independence
The information required by this item is incorporated herein by reference to our 2026 Proxy Statement, including under the headings “Director Independence,” “Review and Approval of Related Party Transactions” and “Related Party Transactions.”
Item 14. Principal Accountant Fees and Services
The information required by this item is incorporated herein by reference to our 2026 Proxy Statement, including under the headings “Independent Registered Public Accounting Firm” and “Policy on Audit Committee Pre-approval of Audit and Permissible Non-audit Services.”
119
Part IV
Item 15. Exhibits and Financial Statement Schedules
The following documents are filed as part of this Annual Report:
(a) (1) Financial Statements
The Consolidated Financial Statements required by this Item are submitted in Part II, Item 8 of this Annual Report.
(2) Financial Statement Schedules
Financial Statement Schedules have been omitted because of the absence of conditions under which they are required or because the required information is included in the Consolidated Financial Statements or the Notes thereto.
(3) Exhibits
See Item 15(b) below.
(b) Exhibits
The Exhibit Index immediately following this Item 15 is filed as part of, and incorporated by reference into, this Annual Report.
(c) Financial Statements Required by Regulation S-X Which Are Excluded from the Annual Report by Exchange Act Rule 14(a)-3(b).
Not applicable.
EXHIBIT INDEX
Exhibit Number Description
2.1+
Business Combination Agreement, dated as of December 22, 2021, by and among Quidel Corporation, Ortho Clinical Diagnostics Holdings plc, Coronado Topco, Inc., Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc. (incorporated by reference to Annex A to the joint proxy statement/prospectus forming part of the Registration Statement on Form S-4 filed by Coronado Topco, Inc. on January 31, 2022)
3.1
Amended and Restated Certificate of Incorporation of QuidelOrtho Corporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Form 8-K filed on May 27, 2022)
3.2
Amended and Restated Bylaws of QuidelOrtho Corporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Form 8-K filed on December 13, 2022)
3.3
Certificate of Change of Registered Agent (incorporated by reference to Exhibit 3.3 to the Registrant’s Form 10-K for the fiscal year ended January 1, 2023 filed on February 23, 2023)
4.1
Specimen Stock Certificate (incorporated by reference to Exhibit 4.1 to the Registrant’s Form 10-Q for the quarter ended July 3, 2022 filed on August 5, 2022)
4.2
Description of QuidelOrtho Corporation’s Securities Registered Pursuant to Section 12 of the Exchange Act of 1934 (incorporated by reference to Exhibit 4.2 to the Registrant’s Form 10-K for the fiscal year ended January 1, 2023 filed on February 23, 2023)
10.1
Credit Agreement, dated as of August 21, 2025, by and among the Company, as borrower, Bank of America, N.A., as administrative agent and swing line lender, and the other lenders and L/C issuers party thereto (incorporated by reference to Exhibit 10.1 to the Registrant’s Form 8-K filed on August 21, 2025 )
10. 2 (1)
QuidelOrtho Corporation Second Amended and Restated 2018 Equity Incentive Plan (incorporated by reference to Exhibit 10. 1 to the Registrant’s Form 8-K filed on May 27, 202 5 )
120
Exhibit Number Description
10. 3 (1)
Form of Restricted Stock Unit Award Grant Notice (incorporated by reference to Exhibit 10.6 to the Registrant’s Form 10-Q for the quarter ended July 3, 2022 filed on August 5, 2022)
10. 4 (1)
Form of Restricted Stock Unit Award Grant Notice (Performance-based) (incorporated by reference to Exhibit 10.7 to the Registrant’s Form 10-Q for the quarter ended July 3, 2022 filed on August 5, 2022)
10. 5 (1)
Form of Restricted Stock Unit Award Grant Notice (Time-based) (incorporated by reference to Exhibit 10.8 to the Registrant’s Form 10-Q for the quarter ended July 3, 2022 filed on August 5, 2022)
10. 6 (1)
Form of Restricted Stock Unit Award Grant Notice (Deferred) (incorporated by reference to Exhibit 10.9 to the Registrant’s Form 10-Q for the quarter ended July 3, 2022 filed on August 5, 2022)
10. 7 (1)
Form of Notice of Grant of Nonqualified Stock Options and Option Agreement (incorporated by reference to Exhibit 10.10 to the Registrant’s Form 10-Q for the quarter ended July 3, 2022 filed on August 5, 2022)
10. 8 (1)
Form of Phantom Stock Unit Award Grant Notice (incorporated by reference to Exhibit 10.11 to the Registrant’s Form 10-Q for the quarter ended July 3, 2022 filed on August 5, 2022)
10. 9 (1)
QuidelOrtho Corporation Amended and Restated 1983 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.4 to the Registrant’s Form 8-K filed on May 27, 2022)
10.1 0 (1)
Employment Offer Letter, dated April 30, 2024, between QuidelOrtho Corporation and Brian J. Blaser (incorporated by reference to Exhibit 10.1 to the Registrant’s Form 8-K filed on May 7, 2024)
10.1 1 (1)
Certain compensation arrangements between QuidelOrtho Corporation and Joseph M. Busky (incorporated by reference to Item 5.02 of the Registrant’s Form 8-K/A filed on February 29, 2024)
10.1 2 (1)
Certain compensation arrangements between QuidelOrtho Corporation and Joseph M. Busky (incorporated by reference to Item 5.02 of the Registrant’s Form 8-K filed on November 18, 2024)
10.1 3 (1)
Form of Integration and Retention Bonus Letter (incorporated by reference to Exhibit 10.4 to the Registrant’s Form 8-K filed on February 4, 2022)
10.1 4 (1)
Form of Indemnification Agreement (incorporated by reference to Exhibit 10.10 to the Registrant’s Form 8-K filed on May 27, 2022)
10.1 5 (1)
Form of Severance and Change in Control Agreement (incorporated by reference to Exhibit 10.18 to the Registrant’s Form 10-K for the fiscal year ended December 29, 2024 filed on February 27, 2025)
10.1 6 (1)
QuidelOrtho Board Deferred Compensation Plan (incorporated by reference to Exhibit 10.19 to the Registrant’s Form 10-K for the fiscal year ended December 31, 2023 filed on February 29, 2024)
10. 17 (1)
QuidelOrtho Employee Deferred Compensation Plan (incorporated by reference to Exhibit 10. 1 to the Registrant’s Form 10-Q for the quarter ended March 30, 2025 filed on May 8, 2025 )
10. 18 (1)
Form of Retention Compensation Agreement for Joseph M. Busy and Michelle A. Hodges (incorporated by reference to Exhibit 10.3 to the Registrant’s Form 10-Q for the quarter ended June 30, 2024 filed on August 1, 2024 )
10. 19 (1)
Form of Retention and Recognition Compensation Agreement for Philip D. McLellan (incorporated by reference to Exhibit 10.3 to the Registrant’s Form 10-Q for the quarter ended March 30, 2025 filed on May 8, 2025)
10. 20 (1)
Employment Offer Letter, dated September 16, 2024, between QuidelOrtho Corporation and Jonathan Siegrist (incorporated by reference to Exhibit 10.4 to the Registrant’s Form 10-Q for the quarter ended March 30, 2025 filed on May 8, 2025)
10.2 1
Summers Ridge Lease (incorporated by reference to Exhibit 10.1 to the Registrant’s Form 8-K filed on January 9, 2018)
10.2 2
Master Agreement, dated as of July 24, 2021, by and among Quidel Corporation, Quidel Cardiovascular, Inc., and Beckman Coulter, Inc. (incorporated by reference to Exhibit 10.1 to the Registrant’s Form 8-K filed on July 26, 2021)
16.1
Letter from Ernst & Young LLP, dated March 3, 2025 (incorporated by reference to Exhibit 16.1 to the Registrant’s Form 8-K filed on March 4, 2025)
19.1
QuidelOrtho Insider Trading Compliance Policy (incorporated by reference to Exhibit 19.1 to the Registrant’s Form 10-Q for the quarter ended September 28, 2025 filed on November 6, 2025)
121
Exhibit Number Description
21.1*
Subsidiaries of QuidelOrtho Corporation
23.1*
Consent of Independent Registered Public Accounting Firm
23.2*
Consent of Independent Registered Public Accounting Firm
31.1*
Certification by Principal Executive Officer of QuidelOrtho Corporation pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*
Certification by Principal Financial Officer of QuidelOrtho Corporation pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**
Certifications by Principal Executive Officer and Principal Financial Officer of QuidelOrtho Corporation pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
97.1
QuidelOrtho Clawback Policy (incorporated by reference to Exhibit 97.1 to the Registrant’s Form 10-K for the fiscal year ended December 29, 2024 filed on February 27, 2025)
101* The following financial statements from the Registrant’s Annual Report on Form 10-K for the year ended December 28, 2025, formatted in Inline XBRL: (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Loss, (iii) Consolidated Statements of Comprehensive (Loss) Income, (iv) Consolidated Statements of Stockholders’ Equity, (v) Consolidated Statements of Cash Flows, and (vi) Notes to Consolidated Financial Statements, tagged as blocks of text and including detailed tags
104 The cover page from the Registrant’s Annual Report on Form 10-K for the year ended December 28, 2025, formatted in Inline XBRL (included as Exhibit 101)
* Filed herewith.
** Furnished herewith.
(1) Indicates a management plan or compensatory plan or arrangement.
+ Certain identified information has been omitted by means of marking such information with asterisks in reliance on Items 601(b)(2)(ii) and 601(b)(10)(iv) of Regulation S-K, as applicable, because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.
Item 16. Form 10-K Summary
None.
122
SUMMARY OF ABBREVIATED TERMS
QuidelOrtho Corporation and its consolidated subsidiaries may be referred to as QuidelOrtho, the Company, we, our or us in this Annual Report, unless the context otherwise indicates. Throughout this Annual Report, we have used terms which are defined below:
ABO
Accumulated benefit obligation
Annual Report Annual Report on Form 10-K for the fiscal year ended December 28, 2025
AOCI Accumulated other comprehensive loss
ASC Accounting Standards Codification
ASU Accounting Standards Update
Audit Committee Audit Committee of the Board
BARDA Biomedical Advanced Research and Development Authority
BLA Biologics License Application
Board Board of directors
CAT Column agglutination technology
CCPA California Privacy Rights Act of 2020
CEO Chief Executive Officer
CFO Chief Financial Officer
cGMPs Current good manufacturing practices
CIIOs Critical information infrastructure
CISO Chief Information Security Officer
CLIA The FDA’s Clinical Laboratory Improvement Amendment of 1988
CMS Centers for Medicare & Medicaid Services
CODM Chief Operating Decision Maker
Combinations Business combination consummated by Quidel and Ortho on May 27, 2022, pursuant to the Business Combination Agreement entered into as of December 22, 2021, by and among Quidel, Ortho, QuidelOrtho (formerly Coronado Topco, Inc.), Orca Holdco, Inc., Laguna Merger Sub, Inc., and Orca Holdco 2, Inc.
Credit Agreement Credit agreement, dated August 21, 2025, by and among the Company, as borrower, Bank of America, N.A., as administrative agent and swing line lender, and the other lenders and
L/C issuers party thereto
CRL Complete Response Letter
EBITDA Earnings before interest, taxes, depreciation and amortization
EEA European Economic Area
EMEA Europe, the Middle East and Africa
EPS Loss per share
ERP Enterprise resource planning
ESPP QuidelOrtho Corporation Amended and Restated 1983 Employee Stock Purchase Plan
EU European Union
EU IVDR EU In Vitro Diagnostic Regulation (EU 2017/746)
EU MDR EU Medical Device Regulation (EU 2017/745)
EUA Emergency use authorization
Exchange Act Securities Exchange Act of 1934, as amended
FASB Financial Accounting Standards Board
FCA False Claims Act
FCPA U.S. Foreign Corrupt Practices Act
FDA U.S. Food and Drug Administration
FDCA U.S. Federal Food, Drug, and Cosmetic Act
123
Financing The Term Loan together with the Revolving Credit Facility
FTC Federal Trade Commission
GAAP Generally accepted accounting principles in the U.S.
GDPR General Data Protection Regulation 2016/679
Grifols Grifols Diagnostic Solutions, Inc.
Grifols Agreement
Agreement governing the Company’s Joint Business between Ortho Inc. and Grifols, originally entered into in 1989 with a 50-year term, as amended
HHS
U.S. Department of Health and Human Services
HIPAA
Health Insurance Portability and Accountability Act of 1996
IND
Investigational New Drug Application
IPR&D
In-process research and development
ISO International Organization for Standardization
IT Information technology
IVD In vitro diagnostics
Joint Business Collaboration arrangement between Ortho and Grifols
JPAC Japan and Asia Pacific
MACRA The Medicare Access and CHIP Reauthorization Act of 2015
MDSAP Medical Device Single Audit Program
NMPA China’s National Medical Products Administration, formerly CFDA
NOL Net operating loss
OBBBA One Big Beautiful Bill Act
OCI Other comprehensive income (loss)
Optimization Plan Multi-year, enterprise-wide cost-reduction, strategic productivity and margin improvement initiatives that the Company launched in the second quarter of 2025
Ortho Ortho Clinical Diagnostics Holdings plc
OTC Over-the-counter
PAMA Protecting Access to Medicare Act of 2014
PBO Projected benefit obligations
PCR Polymerase chain reaction
PHI Protected health information
PIPEDA Canada’s Personal Information Protection and Electronic Documents Act
PIPL China’s Personal Information Protection Law
PMA Premarket approval
POC Point-of-care
POL Physician office laboratory
PPACA The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act
Prior Credit Agreement Credit agreement, dated May 27, 2022, by and among the Company, as borrower, Bank of America, N.A., as administrative agent and swing line lender, and the other lenders and L/C issuers party thereto
QMS Quality Management System
QSR Quality System Regulation
Quidel Quidel Corporation
R&D Research and development
124
RPA Receivables purchase agreement, as amended on March 31, 2023, by and among Ortho-Clinical Diagnostics US FinanceCo I, LLC, as Seller, our wholly owned receivables financing subsidiary, Wells Fargo Bank, N.A., as administrative agent, Ortho-Clinical Diagnostics, Inc., as the Master Servicer and as an Originator, Quidel, as an Originator, and certain Purchasers
Revolving Credit Facility $700.0 million revolving credit facility under the Credit Agreement
ROU Right-of-use
RSUs Restricted stock units; includes time-based RSUs, performance-based RSUs and restricted stock awards
RSV Respiratory syncytial virus
SAVANNA Exit
Discontinuation of the development of the SAVANNA platform
SCCs Standard contractual clauses
SEC Securities and Exchange Commission
Securities Act Securities Act of 1933, as amended
SGC Security Governance Committee
SOFR Secured overnight financing rate
Stock Repurchase Program A stock repurchase program allowing the Company to repurchase up to $300.0 million of its common stock through August 17, 2024, which was authorized by our Board of Directors on August 17, 2022
Term Loans Collectively under the Credit Agreement: (i) a $1.15 billion senior secured term loan A facility (the “Term Loan A”), (ii) a $100.0 million senior secured delayed draw term loan A facility (the “DDTL Term Loan A”; together with the Term Loan A, the “Term Loan A Facilities”), and (iii) a $1.45 billion senior secured term loan B facility (the “Term Loan B”)
U.K. United Kingdom
U.K. ICO U.K. Information Commissioner’s Office
U.K. IDTA U.K. International Data Transfer Agreement
U.S. United States
USD United States dollar
VIP ORTHO VERSEIA Integrated Processor
125
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.
Q UIDEL O RTHO C ORPORATION
By /s/ B RIAN J. B LASER
Date: February 18, 2026
Brian J. Blaser
President and Chief Executive Officer
(Principal Executive Officer)
Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
Signature Title Date
/s/ B RIAN J. B LASER
President and Chief Executive Officer
(Principal Executive Officer) February 18, 2026
Brian J. Blaser
/s/ J OSEPH M. B USKY
Chief Financial Officer
(Principal Financial and Accounting Officer) February 18, 2026
Joseph M. Busky
/s/ K ENNETH F. B UECHLER
Chairman of the Board February 18, 2026
Kenneth F. Buechler
/s/ J OHN R. C HIMINSKI
Director February 18, 2026
John R. Chiminski
/s/ E VELYN S. D ILSAVER
Director February 18, 2026
Evelyn S. Dilsaver
/s/ R ICHARD S. H UENNEKENS
Director February 18, 2026
Richard S. Huennekens
/s/ E DWARD L. M ICHAEL
Director February 18, 2026
Edward L. Michael
/s/ M ARY L AKE P OLAN
Director February 18, 2026
Mary Lake Polan
/s/ A NN D. R HOADS
Director February 18, 2026
Ann D. Rhoads
/s/ M ATTHEW W. S TROBECK
Director February 18, 2026
Matthew W. Strobeck
/s/ K ENNETH J. W IDDER
Director February 18, 2026
Kenneth J. Widder
/s/ J OSEPH D. W ILKINS J R .
Director February 18, 2026
Joseph D. Wilkins Jr.
126